Neurofibromin in bone disease: Mechanisms and therapeutic implications (Review)
Abstract
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder caused by pathogenic mutations in the NF1 gene, which encodes neurofibromin, a critical tumor suppressor and regulator of intracellular signaling. NF1 is a multisystem disease characterized by café‑au‑lait macules, neurofibromas, learning disabilities and prominent skeletal abnormalities. Accumulating evidence has demonstrated that neurofibromin is essential for maintaining skeletal homeostasis and a loss of neurofibromin results in dysregulated signaling pathways, particularly RAS/MAPK and PI3K/AKT. This dysregulation leads to NF1‑associated skeletal diseases, such as low bone mineral density, osteoporosis, congenital pseudarthrosis of the tibia and scoliosis through disordered bone remodeling. Despite substantial progress being made in elucidating the molecular and cellular mechanisms underlying NF1‑associated skeletal diseases, clinical management remains challenging. Skeletal abnormalities often present early in childhood and may progress despite intervention, highlighting the need for timely and effective assessment strategies. Current treatments for NF1 rely largely on complex surgical reconstruction and supportive medical therapy, with variable long‑term outcomes. The present review summarizes the current understanding of the role of neurofibromin in bone homeostasis, discusses the cellular and molecular mechanisms driving NF1‑associated skeletal diseases, and examines emerging assessment tools…
Read the paper
Related studies
- Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study
- Osteoporosis-related fractures after spinal cord injury: a retrospective study from Brazil
- Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men
- Lack of Association between Vitamin D Insufficiency and Cardiovascular or Fracture Risk: A UK Biobank Study
- Muscle strength and body composition are clinical indicators of osteoporosis
- Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.